

Fig. 52

52 / 129

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis
	Diversity	Equivalence	Total (+) Vs (-)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Total (+) vs (-)
DR	Diversity		Total	Total		Stomach	Stomach		Other cancers
5	arp_25	K=R		K(-)>hetero, Rhomo>hetero	RR78.8			RR71.4	
6	arp_24	FL	F=L		FI66.7	F(-)>(+)		LI60.9	
13	arp_17	AT	A=T	Ahomo>hetero, T(-) >hetero	AA76.6			AA67.8	
14	arp_16	AV	A=V	A(-)>hetero, Vhomo>hetero	VV78.8			VV71.4	
29	arp_1	AS	A=S		SS83.36			SS100	A(+)>(-), St- >(+) A Shomohetero> (-)
33	arp4	OR	O=R		OR68.3			RR68.1	
38	arp9	EKW	9K=11D=26Y=28H=30G		KW74.2			KW75.8	
39	arp10	EOY	10E=31V=38A=40Y= (166Q)=(166R)		EY83.3			EY75	
40	arp11	DGLPSV	11G=13Y=14E=14=K25 Q=25R=30L, 11S=12K=12T, 11P=13R	V(-)>hetero	GV100, LL100Q		Vhetero>(-)	LL100	Phetero>homo
41	arp12	KT			KK66.5			TT70.7	
42	arp13	FGHRSY	13F=31F=31I		HY100, FR71.6			SY100, GR75.4	F(+)>(-) Phetero>(-), Shetero(-) >homo
43	arp14	EK	E=K		EE66.2		Qhetero> homo	EK80	
45	arp16	HOY			HQ71.50			HQ830	
55	arp25	OR	O=R				Lhetero> homo	LY80.3	Phetero>homo
55	arp26	FLY			LY70.2				
57	arp28	DEH	28H=30G		DE69.2			DE69.4	
59	arp30	CDHLRY	30H=37L=38L=85A=85V		CC100Q			CC100Q	
60	arp31	FIV	31V=38A=40F=40Y, 31 (F=I)		FV77.8			FV76.2	(+)>(-) Phetero>homo (hetero>(-))

Fig. 53

53 / 129

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Total (+) vs (-)	Total (homo)
DR	Diversity		Total	Total		Stomach	Stomach		Other cancers	Other cancers
61	arp32	HY	H=Y		HY66.9			YY68		
62	arp33	HN	H=N		NN66.7			HH71.4		
66	arp37	FLNSY	F=S		LL800			FS73.4		F(-) hetero>homo
67	arp38	ALV			LL800			AV78.8		
69	arp40	FY	F=Y		FY73.1			FY71.6		
76	arp47	FY	F=Y		FY67.4			YF68.9		
86	arp57	ADSV		Shetero (-)>homo	AV73.70			AD72.5, SV72.5		Shetero (-)> homo
87	arp58	AE	A=E		AE67			AE71.1		
89	arp60	HAY			HS73.7			HY68.4		
96	arp67	FIL			FI68.5			FI72.2		
99	arp70	DQR			DD69.4			DD72.7		
100	arp71	AEKR		K(-)>hetero	AR63.5, ER67.2, AE72.6		K(-)>(+)	K(-)>hetero		A.Ehetero> homo
	arp73	AG	73A=73G=74R=74N= 77N=77T		AA66.3			AA68.1		
103	arp74	AELOR	R=N		LR80			AO100.0		
106	arp77	NT	N=T		TT66.4			TT68.2		
107	arp78	VY	V=Y		VY67.1			VY68.6		

54 / 129

Fig. 54

	Diversity	Equivalence	Prognosis		Prognosis		Prognosis		Prognosis		Prognosis		Prognosis		Prognosis	
			Total (+) vs (-)	Total	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Other cancers	Total (+) vs (-)	Total (homo)	Stomach	Other cancers	Total (+) vs (-)	Total (homo)
DR	Diversity		Total	Total												
114	arp85	AV	A=V			AA80							VV68.1			
115	arp86	GV	G=V			GG68.5							VV69.4			
125	arp96	EHQY				EE100							EE100			Q(-) hetero>homo
127	arp98	EK	98E=98K=104A=142V			EK68.5							EK72.1			
133	arp104	AS	A=S			AS70.5							AS72.1			
149	arp120	NS	S=N		N(-) >hetero Stomo>h etero	NN77.9							NN72.9			
162	arp133	LR	133L=133R=142M=142V			RR67.5							LL69.7	R(+)>(-)		
169	arp140	AT				TT71.5							TT74.1			
171	arp142	MV	M=V			VV67.5							MM69.7	V(+)>(-)		
178	arp149	HQY	H=Q			HH68.1							HH70.8			
195	arp166	QR	Q=R			RR67							QR68.6			
209	arp180	LV	L=V			LL75.1							RR68.6			
210	arp181	MT				TT67.3							LL70.1			
218	arp189	RS	R=S			SS100							TT69			
260	arp231	PQ	P=Q			QQ66.7							SS100			
262	arp233	RT	R=T			TT67.4	T(+)>(+)	R Thomo>h etero(-)					QQ67.9			R Thetero(-) >homo
	All survived					DR11GLGV LL(5)							DR30CLC C(4)			

Fig. 55

			Prognosis	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect
	Diversit	Equivalence	Other cancers	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)	Total (homo)
DR	Diversit			Total	Total		Stomach	Stomach
arp_25	KR	K=R	RR100					
arp_24	FL	F=L	FL100					
arp_17	AT	A=T	AA100		Immunotherapy AA 71.4			
arp16	AV	A=V	VV100					
arp1	AS	A=S	AA90.90					
arp4	OR	Q=R	QQ69.3					
arp9	EKW	9K=11D=26Y=28 H=30G	KW71.2		Immunotherapy KW (86.7)			Immunotherapy KW 84.6
arp10	EOY	10E=31V=38A=4 0Y=(166Q)=(166 R)	EY100	Immunotherapy E(-)>(+))	Immunotherapy E(-) >hetero		Immunotherap y E(-)>(+))	Immunotherapy E(-) >hetero
arp11	DGLPS V	11G=13V=14E=1 4=K25Q=25R=3 0L, 11S=12K=12T, 11P=13R	LL1000		Immunotherapy Vhomo,((-)>hetero	no adjuvant therapy DS(83.4)DV(79.6), Immunotherapy DP (84.6)		Immunotherapy Vhomo,((-))>hetero
arp12	KT		KK64.2					
arp13	FGHRS Y	13F=13F=31I	FR74.20	Immunotherapy Shetero>(-) ,homo		no adjuvant therapy GH(89.9) Immunotherapy FS(81.9)		Immunotherapy Hhomo,((-))>hetero
arp14	EK	E=K	EE63.5					
arp16	HQY		QY100					
arp25	OR	Q=R						
arp26	FLY		LL100	Chemotherapy 26L(+)>(-)	Chemotherapy Lhetero>(-)homo, Immunotherapy Lhetero (-)>homo	no adjuvant therapy FL(87), immunotherapy FL(61.4)		Chemotherapy Lhetero,((-))>homo, Immunotherapy Lhetero (-)>homo
arp28	DEH	28H=30G	EE63.3					Immunotherapy Ehetero,(-)>homo
arp30	CGHLR Y	30H=37L=38L=8 5A=85V	CC100	no adjuvant therapy H(+)>(-) Immunotherapy R(-)>(+))	Immunotherapy R(-) >hetero		Immunotherap y R(-)>(+))	
arp31	FIV	31V=38A=40F=4 0Y, 31(F=I)	FV80	Immunotherapy V(-)>(+))	Immunotherapy V(-) >hetero	Immunotherapy FF (55.5), FI(60.7)	Immunotherap y V(-)>(+))	Immunotherapy V(-) >hetero

Fig. 56

56 / 129

			Prognosis	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	
	Diversity	Equivalence	Other cancers	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)	Total (homo)	
DR	Diversity			Total			Stomach	Stomach	
arp32	HY	H=Y	HY64.8				Immunotherapy N(-)>P(+)	Immunotherapy F(homo>(-)) hetero, Immunotherapy N(-)>P(homo), hetero	Immunotherapy HH(67.5)
arp33	HN	H=N	HN64.5						
arp37	FLNSY	F=S	FL63.30	Chemotherapy F(-)>P(+) no adjuvant therapy L (+)>P(-), Immunotherapy N(+)>P(-)	Chemotherapy F(-) >hetero, homo, Immunotherapy N(hetero, (homo)>(-))	Chemotherapy LY(70.9), Immunotherapy NS(72.5)			Immunotherapy NS(69.1)
arp38	ALV		LL100	Immunotherapy A(-)>P(+) no adjuvant therapy L(+)>P(-)	Immunotherapy A(-) >hetero		Immunotherapy A(-)>P(+)	Immunotherapy A(-) >hetero	
arp40	FY	F=Y	FY75	Immunotherapy Y(-)>P(+)	Immunotherapy F(homo>hetero, Immunotherapy Y(-) >hetero	Immunotherapy FF(67.5)			
arp47	FY	F=Y	FY67.3						Chemotherapy FF(74.5)
arp57	ADSV		AV68.90	Chemotherapy A(-)>P(+)	no adjuvant therapy Shetero((-))>homo	no adjuvant therapy SV(92.2), Chemotherapy DD(60.3), Immunotherapy AD(76.2)			no adjuvant therapy SV(100), Immunotherapy AD(83.3)
arp58	AE	A=E	AA63.5	Chemotherapy H(-)>P(+)		Chemotherapy YY(56.8)			
arp60	HAY		HS68.9	Immunotherapy H(-)>P(+)	Immunotherapy H(-) >homo, hetero, no adjuvant therapy L(hetero>(-)) homo, Chemotherapy L(-) >hetero, homo				Chemotherapy H(74.8)
arp67	FIL		FF72.4	Chemotherapy L(-)>P(+)					
arp70	QCR		RR69.4	Chemotherapy R(-)>P(+)					no adjuvant therapy DQ (86.5)
arp71	AEKR		KR78.80	no adjuvant therapy K(-) >P(+)	no adjuvant therapy A(hetero, (-))>homo, E(hetero, (-))>homo	no adjuvant therapy RR(81.6), Immunotherapy ER(73.7)	no adjuvant therapy K(-)>P(+)		no adjuvant therapy ER(91.7), Chemotherapy AA(77.8)
arp73	AG	73A=73G=74 R=74N=77N=77I	AG66.6				Chemotherapy G(-)>P(+)	Chemotherapy A(homo>hetero, Chemotherapy G(-)>P(hetero)	Chemotherapy AA(58)
arp74	AELOK	R=N	ER1000	Chemotherapy E(-)>P(+) Immunotherapy E(+)>P(-)	Immunotherapy A(hetero, (-))>homo, Immunotherapy E(hetero, homo>(-))	Immunotherapy AE(67.9)	Chemotherapy R(-)>P(+)	Immunotherapy A(hetero((-)) homo, Chemotherapy(-)>hetero	no adjuvant therapy EL(90.9), Chemotherapy AL(66.1), Immunotherapy AE(67.5)
arp77	NT	N=I	NT83.3				Chemotherapy N(-)>P(+)	Chemotherapy N(-) >hetero, Chemotherapy Thomo>hetero	Chemotherapy TT(56)
arp78	VY	V=Y	VV69.3						

58 / 129

Fig. 58

			Treatment Effect	Treatment Effect	DR	DR	DR	DR	DR
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metastases	Total (ratio of advanced cancer)	Smoking
DR	Diversity		Other cancers	Other cancers					
arp 25	KR	K=R							
arp 24	FL	F=L					FLB01L22.90		
arp 17	AT	A=T							
arp 16	AV	A=V							
arp 1	AS	A=S			no adjuvant therapy AA (100)				AS703 AAA4.40
arp4	OR	O=R							
arp9	EKW	8K=11D=26Y =28H=30G	no adjuvant therapy Whetelo (-) >homo		no adjuvant therapy KM(85.8)				
arp10	EQY	10E=31V=38A =40Y=(166Q) =(166R)							
arp11	DGLPSV	11G=13Y=14 E=14=K25Q= 25R=30L 11S=12K=12T .11P=13R	no adjuvant therapy Phetelo (-) >homo						
arp12	KT								
arp13	FGHRSY	13F=31F=31I	no adjuvant therapy Rhelelo (-) >homo Chemotherapy Shetelo (-)->homo Immunotherapy Shetelo (-)->homo		no adjuvant therapy FR(90) Chemotherapy FR(72) Immunotherapy FS(100)			FT22.6, FF0, GR0, O	
arp14	EK	E=K							
arp16	HOY							QQ100, YY6, 30	
arp25	OR	O=R							
arp26	FLY		Chemotherapy F(-) (hetero)->homo						
arp28	DEH	28H=30G			Chemotherapy EE(100)				
arp30	CDHLRY	30H=37L=38L =85A=86V							
arp31	FIV	31V=38A=40F =40Y, 31(F=I)							

59 / 129

Fig. 59

	Diversity	Equivalence	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	DR Cancer in Family	DR Metastases	DR Total (ratio of advanced cancer)	DR Smoking
DR	Diversity	H=Y	Other cancers Chemotherapy Y(+) > (-) Immunotherapy Y(+) > (-) Chemotherapy H(+) > (+)	Other cancers Chemotherapy H(-) Yhetero-homo Immunotherapy hetero (-) Yhetero-homo(-) Yhetero-homo(-) Yhetero-homo(-)	Chemotherapy HY(55.6) Immunotherapy HY(55.6)				
arp32	HY	H=Y							
arp33	HN	H=N						HN18.3, NN9.80	
arp37	FLNSY	F=S		Chemotherapy F(-) Y(hetero) > homo, no adjuvant therapy Shetero (-) Yhomo	no adjuvant therapy YY(81.3) Chemotherapy FS(100) Immunotherapy NS(60)				
arp38	ALV					#			
arp40	FY	F=Y							
arp47	FY	F=Y							
arp57	ADSV		Chemotherapy A(-) > (+)	Chemotherapy A(-) > Yhetero, homo Immunotherapy Shetero (-) Yhomo	no adjuvant therapy SV(81.8) Chemotherapy VY(85.7) Immunotherapy DS(78.8)				
arp58	AE	A=E							
arp60	HAY			Chemotherapy H(-) Y(hetero) homo	Chemotherapy SS(65.7) Immunotherapy HY(75) no adjuvant therapy FF(85.7) LL(78.3)				
arp67	FIL								
arp70	DQR								
arp71	AEKR			no adjuvant therapy Ahetero, (-) > homo	no adjuvant therapy AR(74.9)				
arp73	AG	73A=73G=74 R=74N=77N=77T							
arp74	AELOR	R=N	no adjuvant therapy L(-) Y(+)	no adjuvant therapy Ahetero, (-) > homo	no adjuvant therapy (AE81) Chemotherapy (AE54.4)				
arp77	NI	N=T							
arp78	VY	V=Y							

Fig. 60

60 / 129

		Treatment Effect	Treatment Effect	Treatment Effect	DR	DR	DR	DR
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metastases	Total (ratio of advanced cancer)
DR	Diversity		Other cancers	Other cancers				
arp85	AV	A=V	Chemotherapy G(+)>P(-)	Chemotherapy Ghomo hetero>(-)	Chemotherapy VV(96)	AV98.7, AA00	#	
arp86	GV	G=V		no adjuvant therapy Q(-)	no adjuvant therapy HY(100)			#
arp96	EHQY			Chemotherapy Ehetero>homo				
arp98	EK	98E=98K=104 A=104S	Immunotherapy K(+)>P(-)	Immunotherapy Ehetero(-)	Immunotherapy EK(66.4)			
arp104	AS	A=S	Immunotherapy S(+)>P(-)	Chemotherapy Khetero,homo>(-)	Immunotherapy AS(61.9)			
arp120	NS	S=N		Immunotherapy Ahetero(-)				
arp133	LR	133L=133R=1 42M=142V	no adjuvant therapy R(+)>P(-)	Immunotherapy Shetero,homo>(-)		#	#	
arp140	AT			no adjuvant therapy Uhetero(-)>phomo, no adjuvant therapy Rhomo hetero>(-)	no adjuvant therapy RR(69.1)			
arp142	MV	M=V	no adjuvant therapy V(+)>P(-)	no adjuvant therapy Mhetero(-)>phomo, no adjuvant therapy Vhomo hetero>(-)	no adjuvant therapy VV(69.1)			
arp149	HQY	H=Q						
arp164	FV							
arp166	OR	O=R						
arp180	LV	L=V			no adjuvant therapy LV(100)	#		
arp181	MT							#
arp189	RS	R=S						
arp231	PO	P=O						
arp333	RT	R=T	Immunotherapy T(+)>P(-)	Immunotherapy Rhetero(-)	Immunotherapy RT(77.9)			
All	survived			Immunotherapy Phetero,homo>(-)				

61 / 129

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Treatment	Treatment	Treatment
			Equivalence	Total (+) vs (-)	Total (nomo)	Total	Total	Total (+) vs (-)	Total (nomo)	Total	Total (+) vs (-)	Effect	Effect	Effect
				Total	Total	Total	Stomach	Stomach	Stomach	Other cancers	Other cancers	Total	Total	All cases
37	app8	LV	8L=8V=9F =11G=11L		LV67.4			VV77.8			LV64.70			
38	app9	FHY			FY68.2			YY85.7			FY65.80			
40	app11	GL	G=L		GL67.3			LL77.8			GL64.70			
64	app35	FLY			FF68			FY76.90			LV68.8			
65	app36	AV	A=V		AA85.7			AA80			AA100			
84	app55	ADE			AA85.7			AA80			AA100			
85	app56	AE			EE67.5			EE70.8			AA67.3			
86	app57	DE			DD68.5			DD76			EE64.2			
94	app65	FL	65L=65L		LL85.7			LL85.7			LL64.6			
98	app69	EK	E=K		EK68.6			EK69.4			EK67.90			
105	app76	IMV			II100			IV100			IM67.70			
113	app84	DG			DG66.9			GG70.8			DG65.9			
114	app85	EG			EG66.9			GG70.8			EG65.9			
115	app86	AP			AP66.9			PP70.8			AP65.9			

Fig. 62

[illegible]

Fig. 63

DP	Diversity	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Stomach cancer	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	Treatment Effect Other cancers	DP	Category (rate of malignancy)	DP
app8	LV	Stomach	Stomach				Other cancers	no adjuvant therapy Vhetero (-) > homo	no adjuvant therapy (LV)	VV95.2 LL89.60	
app9	FHY	Immunotherapy Y H(-) > (+)	Immunotherapy H(-) (homo) > hetero	Immunotherapy FY167.1 FF(65)	no adjuvant therapy F(+ > (-)	no adjuvant therapy Fhetero homo > (-), no adjuvant therapy H(-))hetero > homo	no adjuvant therapy (FY)	#			
app11	GL				no adjuvant therapy G(+ > (-)	no adjuvant therapy Ghetero homo > (-), no adjuvant therapy L(-))hetero > homo	no adjuvant therapy (GL)	VV95.2 LL89.60			
app35	FLY			Chemotherapy (FF)			Chemotherapy (LY)		#		
app36	AV	Chemotherapy A(-) (homo) > hetero Chemotherapy Vhomo (-))hetero	Chemotherapy (VV)								
app55	ADE	Chemotherapy A(-) (homo) > hetero			no adjuvant therapy A(+ > (-)	no adjuvant therapy Ahetero (-) > homo adjuvant therapy Ehetero (-))homo	no adjuvant therapy DE(76.3)	AE44.8 AA18 0			
app56	AE				no adjuvant therapy E(+ > (-)	no adjuvant therapy Ehetero (-) > homo no adjuvant therapy	no adjuvant therapy AE(74.5)				
app57	DE				no adjuvant therapy E(+ > (-)	no adjuvant therapy Dhetero (-) > homo no adjuvant therapy	no adjuvant therapy DE (76.8)	VV96.3 LL89.60			
app58	FIL				no adjuvant therapy L(+ > (-)	no adjuvant therapy Lhetero homo > (-)	no adjuvant therapy LL(100)				
app69	EK	Immunotherapy Y E(-) > (+)	no adjuvant therapy Ehetero > (-) homo Immunotherapy E(-) (hetero) > homo, no adjuvant therapy Khetero (homo) (-), Immunotherapy K homo, hetero > (-)	no adjuvant therapy EK (55.4) Immunotherapy KK (58.3)	no adjuvant therapy K(+ > (-)	no adjuvant therapy Khetero > homo, no adjuvant therapy Lhetero homo > (-), no adjuvant therapy E(-))hetero > homo, no adjuvant therapy Lhetero homo > (-)	no adjuvant therapy EK(77.7)				
app76	IMV		Chemotherapy I(-) (homo) > hetero	Chemotherapy IMV(64)		no adjuvant therapy Vhetero (-) > homo	no adjuvant therapy IMV(79)	VV95.6 LL86.70			
app84	DG							DD92.1 GG87.80			
app85	EG							EE92.1 GG87.60			
app86	AP							VV92.1 MM87.60			